Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Walden Biosciences, Inc.

Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Appoints Howard Mayer, M.D. to Board of Directors
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Highlights 2024 Accomplishments and 2025 Priorities
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Fully Enrolls First Cohort in Phase 2 Basket Study of WAL0921 in Chronic Kidney Diseases
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Announces Research Collaboration with World Renowned Genetic Epidemiologist to Advance Work on Causal Role of suPAR in Chronic Kidney Disease
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Announces Positive Topline Data from Phase 1+ Clinical Study of WAL0921 in Development for Treatment of Kidney Diseases
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Expands Research Collaboration with the University of Michigan
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences to Host Virtual Event on November 14, 2023 “Transforming the Treatment Landscape of Chronic Kidney Disease”
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Announces First Subject Dosed in First-in-Humans Phase 1 Clinical Trial of WAL0921, in Development for Treatment of Chronic Kidney Diseases
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Promotes Curt Dewan, CFA to Chief Financial Officer
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences To Present at 5th Annual Chronic Kidney Disease Drug Development Summit
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Announces Presentation at Antibody Engineering and Therapeutics Conference 2022
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Announces Participation at October Investor Conferences
From Walden Biosciences, Inc.
Via GlobeNewswire
Walden Biosciences Appoints Peter Guest Linde, M.D. as Chief Medical Officer
From Walden Biosciences, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.